Lineage Cell Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Lineage Cell Therapeutics, Inc. (LCTX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $14.75 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-15
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $20.18M.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $2.11M, a 23.17% decline year-over-year.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$9.27M, a 1725.61% decline year-over-year.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $1.73M.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $14.75M.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$20.14M, a 258.07% decline from fiscal 2015.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $12.74M, a 46.89% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $23.99M, a 1993.46% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $20.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $22.29M derived: sum of 2 quarters · filed 2018-03-15 | $13.02M derived: sum of 3 quarters · filed 2018-03-15 | $14.75M 10-K · filed 2018-03-15 | ||||
| 2017-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$7.15M derived: sum of 2 quarters · filed 2017-11-09 | -$5.43M 10-Q · filed 2017-11-09 | -$13.79M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2017-06-30 | -$9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$7.54M 10-Q · filed 2017-08-09 | -$15.90M derived: sum of 3 quarters · filed 2018-03-15 | -$13.15M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2017-03-31 | $1.73M 10-Q · filed 2017-05-10 | -$6.63M derived: sum of 2 quarters · filed 2018-03-15 | -$3.89M derived: sum of 3 quarters · filed 2018-03-15 | -$3.32M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-12-31 | -$8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$5.61M derived: sum of 2 quarters · filed 2018-03-15 | -$5.04M derived: sum of 3 quarters · filed 2018-03-15 | -$20.14M 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.32M derived: sum of 2 quarters · filed 2017-11-09 | -$11.78M 10-Q · filed 2017-11-09 | $1.07M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-06-30 | $570.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$14.53M 10-Q · filed 2017-08-09 | -$1.68M derived: sum of 3 quarters · filed 2018-03-15 | -$3.76M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-03-31 | -$15.10M 10-Q · filed 2017-05-10 | -$2.25M derived: sum of 2 quarters · filed 2018-03-15 | -$4.33M derived: sum of 3 quarters · filed 2018-03-15 | $1.30M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-12-31 | $12.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $10.76M derived: sum of 2 quarters · filed 2018-03-15 | $16.40M derived: sum of 3 quarters · filed 2018-03-15 | $12.74M 10-K · filed 2018-03-15 | ||||
| 2015-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $3.55M derived: sum of 2 quarters · filed 2016-11-04 | -$109.00K 10-Q · filed 2016-11-04 | $21.96M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $1.98M 10-Q · filed 2016-08-09 | $24.05M derived: sum of 3 quarters · filed 2017-03-16 | $15.74M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-03-31 | -$3.66M 10-Q · filed 2016-05-10 | -$3.66M 10-Q · filed 2015-05-08 | $18.41M derived: sum of 2 quarters · filed 2017-03-16 | $10.11M derived: sum of 3 quarters · filed 2017-03-16 | $19.19M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $13.76M derived: sum of 2 quarters · filed 2017-03-16 | $22.85M derived: sum of 3 quarters · filed 2017-03-16 | $23.99M 10-K · filed 2017-03-16 | $23.99M 10-K · filed 2015-03-11 | |||
| 2014-09-30 | -$8.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $778.64K derived: sum of 2 quarters · filed 2015-11-09 | $1.92M 10-Q · filed 2015-11-09 | $1.92M 10-Q · filed 2014-11-07 | $699.62K derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | $9.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $10.23M 10-Q · filed 2015-08-10 | $10.23M 10-Q · filed 2014-08-11 | $9.01M derived: sum of 3 quarters · filed 2016-03-15 | $1.42M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | $1.14M 10-Q · filed 2015-05-08 | -$79.02K derived: sum of 2 quarters · filed 2016-03-15 | -$7.67M derived: sum of 3 quarters · filed 2016-03-15 | -$3.26M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2013-12-31 | -$1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$8.81M derived: sum of 2 quarters · filed 2016-03-15 | -$4.40M derived: sum of 3 quarters · filed 2016-03-15 | $1.15M 10-K · filed 2016-03-15 | $1.15M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | -$7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$3.18M derived: sum of 2 quarters · filed 2014-11-07 | $2.37M 10-Q · filed 2014-11-07 | -$1.11M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $9.96M 10-Q · filed 2014-08-11 | $6.48M derived: sum of 3 quarters · filed 2015-03-11 | $1.65M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2013-03-31 | $5.55M 10-Q · filed 2014-05-12 | $2.07M derived: sum of 2 quarters · filed 2015-03-11 | -$2.76M derived: sum of 3 quarters · filed 2015-03-11 | -$6.59M derived: sum of 4 quarters · filed 2015-03-11 | ||||
| 2012-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | -$8.31M derived: sum of 2 quarters · filed 2015-03-11 | -$12.14M derived: sum of 3 quarters · filed 2015-03-11 | -$17.86M 10-K · filed 2015-03-11 | ||||
| 2012-09-30 | -$4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$8.66M derived: sum of 2 quarters · filed 2013-11-12 | -$14.38M 10-Q · filed 2013-11-12 | -$18.40M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-06-30 | -$3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$9.55M 10-Q · filed 2013-08-09 | -$13.57M derived: sum of 3 quarters · filed 2014-03-17 | -$14.72M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-03-31 | -$5.72M 10-Q · filed 2013-05-10 | -$9.74M derived: sum of 2 quarters · filed 2014-03-17 | -$10.89M derived: sum of 3 quarters · filed 2014-03-17 | -$13.65M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2011-12-31 | -$4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$5.17M derived: sum of 2 quarters · filed 2014-03-17 | -$7.93M derived: sum of 3 quarters · filed 2014-03-17 | -$11.11M 10-K · filed 2014-03-17 | ||||
| 2011-09-30 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$3.91M derived: sum of 2 quarters · filed 2012-11-09 | -$7.09M 10-Q · filed 2012-11-09 | $1.04M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-06-30 | -$2.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$5.94M 10-Q · filed 2012-08-09 | $2.19M derived: sum of 3 quarters · filed 2013-03-18 | $9.54M derived: sum of 4 quarters · filed 2013-03-18 | ||||
| 2011-03-31 | -$3.19M 10-Q · filed 2012-05-10 | $4.95M derived: sum of 2 quarters · filed 2013-03-18 | $12.30M derived: sum of 3 quarters · filed 2013-03-18 | |||||
| 2010-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $15.49M derived: sum of 2 quarters · filed 2013-03-18 | $21.14M 10-K · filed 2013-03-18 | |||||
| 2010-09-30 | $7.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $13.00M 10-Q · filed 2011-11-08 | ||||||
| 2010-06-30 | $5.65M 10-Q · filed 2011-08-09 | |||||||
| 2009-12-31 | $12.18M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |